Study guide
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure
Key Takeaways Explain This Topic AI
After aneurysmal subarachnoid haemorrhage, early securing of the aneurysm (coiling or clipping) prevents rebleeding, and oral nimodipine 60 mg every 4 hours for 21 days improves outcome.
Delayed cerebral ischaemia after subarachnoid haemorrhage peaks at about days 4-14; maintain euvolaemia and treat suspected ischaemia with induced hypertension rather than prophylactic hypervolaemia or haemodilution.
In acute ischaemic stroke, intravenous thrombolysis is given within 4.5 hours of onset (longer in selected patients with imaging selection), and mechanical thrombectomy is effective for large-vessel occlusion, up to 24 hours in selected patients.
Convulsive status epilepticus is treated with a benzodiazepine first (for example lorazepam 4 mg IV, midazolam 10 mg buccal or IM), then a second-line drug such as levetiracetam, valproate or phenytoin, and then anaesthetic agents if seizures persist.
In acute neuromuscular weakness, a vital capacity below about 20 mL/kg, a maximum inspiratory pressure weaker than about -30 cmH2O, or bulbar dysfunction indicates a need for ventilatory support.
Last updated: October 2026
- 22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure
- General Principles
The aims of neurocritical care are to prevent secondary brain injury and to treat the primary cause. Secondary insults include hypoxaemia, hypotension, hypercapnia or excessive hypocapnia, hyperthermia, hypo- and hyperglycaemia, seizures and raised intracranial pressure. The principles of intracranial pressure management are covered in the neurophysiology and neuroanaesthesia sections.
- Aneurysmal Subarachnoid Haemorrhage (SAH)
- Presentation and Grading
Sudden severe ("thunderclap") headache, neck stiffness, vomiting, reduced consciousness and focal signs. Diagnosis: non-contrast CT (very sensitive in the first 6 hours), lumbar puncture for xanthochromia if CT is negative after 6 hours, and CT angiography to identify the aneurysm.
Scale Basis Use
World Federation of Neurosurgical Societies (WFNS) Glasgow Coma Scale and focal motor deficit (grades I-V) Clinical severity and prognosis
- Hunt and Hess Clinical features (grades I-V) Clinical severity
- Modified Fisher Amount of blood on CT Risk of vasospasm and delayed cerebral ischaemia
- Early Management
Secure the airway if GCS is 8 or less; avoid hypoxaemia and hypercapnia.
Control blood pressure before the aneurysm is secured (commonly systolic below about 160 mmHg), balancing rebleeding risk against cerebral perfusion.
Nimodipine 60 mg orally (or enterally) every 4 hours for 21 days reduces poor outcomes; intravenous nimodipine causes more hypotension.
Secure the aneurysm early (ideally within 24-72 hours) by endovascular coiling or surgical clipping. The ISAT trial showed better 1-year independence with coiling for suitable aneurysms.
Antifibrinolytics are not routinely recommended (the ULTRA trial showed no improvement in outcome).
Complications
- Complication Timing Features and treatment
- Rebleeding Highest in the first 24 hours High mortality; prevented by early securing of the aneurysm
- Hydrocephalus Acute or delayed External ventricular drain
Delayed cerebral ischaemia Days 4-14 New focal deficit or fall in GCS; maintain euvolaemia; induced hypertension for symptomatic ischaemia; endovascular therapy (angioplasty, intra-arterial vasodilators) for refractory vasospasm
Hyponatraemia Days 3-10 SIADH or cerebral salt wasting; avoid fluid restriction (risk of ischaemia); use saline and fludrocortisone
Neurogenic cardiac injury Early Raised troponin, ECG changes, stress cardiomyopathy, neurogenic pulmonary oedema
Seizures Any time Treat; routine prophylaxis is debated
The old "triple-H" therapy (hypertension, hypervolaemia, haemodilution) has been abandoned; prophylactic hypervolaemia causes complications without benefit.
- Acute Stroke
- Ischaemic Stroke
Thrombolysis: alteplase 0.9 mg/kg (10% bolus, rest over 1 hour, maximum 90 mg) or tenecteplase within 4.5 hours of onset after CT excludes haemorrhage; selected patients with unknown onset may be treated using advanced imaging.
Mechanical thrombectomy for proximal anterior circulation large-vessel occlusion, within 6 hours and up to 24 hours in selected patients with salvageable tissue on imaging.
Blood pressure: keep below 185/110 mmHg before thrombolysis and below 180/105 mmHg for 24 hours afterwards.
Anaesthesia for thrombectomy: conscious sedation or general anaesthesia are both acceptable; avoid hypotension and delays.
Malignant middle cerebral artery infarction: decompressive hemicraniectomy within 48 hours reduces mortality in selected patients under about 60 years.
Intracerebral Haemorrhage
Rapid blood pressure lowering to a systolic target of about 140 mmHg (avoiding falls below about 110-120 mmHg) is considered safe.
Reverse anticoagulation promptly: prothrombin complex concentrate and vitamin K for warfarin, idarucizumab for dabigatran, andexanet alfa or prothrombin complex concentrate for factor Xa inhibitors.
Platelet transfusion is not beneficial for patients on antiplatelet drugs who are not having surgery (PATCH trial).
Status Epilepticus
Convulsive status epilepticus is now defined as seizure activity lasting 5 minutes or more (time point t1), or recurrent seizures without recovery; long-term consequences become likely after about 30 minutes (t2). 0-5 min ABC, oxygen, glucose check (give glucose if low; thiamine first if alcohol misuse)
5-20 min FIRST LINE - benzodiazepine:
- lorazepam 4 mg IV (repeat once), or diazepam 10 mg IV,
- or midazolam 10 mg buccal/IM if no IV access
20-40 min SECOND LINE - one of:
- levetiracetam 60 mg/kg (max 4,500 mg), sodium valproate 40 mg/kg (max 3,000 mg),
- or fosphenytoin/phenytoin 20 mg/kg PE (ESETT: similar efficacy)
- 40-60 min REFRACTORY - general anaesthesia with propofol, midazolam or thiopental;
- intubate, ventilate, continuous EEG to confirm seizure suppression
Avoid valproate in women of childbearing potential where possible and in liver disease; phenytoin needs ECG monitoring (arrhythmias, hypotension) and causes tissue injury if extravasated.
Non-convulsive status may follow; continuous EEG is needed in patients who do not wake.
Look for causes: drug withdrawal, hypoglycaemia, hyponatraemia, infection, alcohol, eclampsia, structural lesions.
Acute Spinal Cord Injury
Immobilise appropriately, and use manual in-line stabilisation during intubation; videolaryngoscopy reduces cervical movement.
Maintain mean arterial pressure of about 85-90 mmHg for the first 5-7 days in some guidelines to support cord perfusion; treat neurogenic shock with fluids, vasopressors and atropine for bradycardia.
High-dose methylprednisolone is no longer recommended routinely.
Suxamethonium is safe only in the first 24-48 hours after injury.
Lesions at C3-C5 affect diaphragmatic function and often need ventilation.
- Acute Neuromuscular Respiratory Failure
- Guillain-Barré Syndrome
Ascending weakness, areflexia and autonomic instability, often after infection (for example Campylobacter ).
Intravenous immunoglobulin (0.4 g/kg/day for 5 days) or plasma exchange are equally effective; corticosteroids are not.
About 20-30% need mechanical ventilation.
Myasthenic Crisis
Respiratory failure from myasthenia gravis, often triggered by infection, surgery or drugs (aminoglycosides, magnesium, fluoroquinolones). Treat with ventilatory support, plasma exchange or immunoglobulin, and corticosteroids, and temporarily withhold anticholinesterases in ventilated patients to reduce secretions.
Criteria for Ventilation (the "20/30/40 rule")
- Measurement Threshold for concern
- Vital capacity Below about 20 mL/kg
- Maximum inspiratory pressure Weaker than about -30 cmH2O
- Maximum expiratory pressure Below about 40 cmH2O
Other indications include bulbar dysfunction with aspiration risk, a rising P a CO 2 P_a\text{CO}_2 P a CO 2 or a rapid decline. Oxygen saturation and blood gases are late markers in neuromuscular failure, so serial vital capacity is essential.